A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Recombinant human endostatin is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells. Endu is a modified version of endostatin. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin. In June 2007, the company acquired an additional 10% equity interest in Yantai Medgenn. The company is conducting Phase IV clinical trials for Endu in approximately 150 hospitals in China.
Multicolumn countercurrent solvent gradient purification (MCSGP) is a form of chromatography that is used to separate or purify biomolecules from complex mixtures. It was developed at the Swiss Federal Institute of Technology Zürich by Aumann and Morbidelli. The process consists of two to six chromatographic columns which are connected to one another in such a way that as the mixture moves through the columns the compound is purified into several fractions.
Directed by David Cohen, made by Psychology News 7 November Life and Art, about assisted reproductive technology (ART) and zygote intrafallopian transfer; Debra Hauer gives a talk at Acland Burghley School; Hossam Abdalla (now on the Human Tissue Authority at the Lister Hospital, Chelsea; the assisted zona hatching technique; intracytoplasmic sperm injection; Robert Winston, Baron Winston of Hammersmith Hospital. Directed by Debra Hauer, produced by Christopher Rawlence, made by Hauer Rawlence 21 November Building for Earthquakes, earthquake engineering in Mexico City; Edward Bortugno of the Office of Emergency Services, California; structural engineer Enrique Martinez Romero of Mexico, and the building of the Mexican Social Security Institute; an earthquake was expected near Acapulco in the next ten years; the North Anatolian Fault is the world's most energetic fault; seismologist Polat Gulkan of the Middle East Technical University; Attilla Ansal, editor of the Bulletin of Earthquake Engineering; Müzeher Erciyastepe of the İnşaat Mühendisleri Odası (IMO, Chamber of Engineers); the gecekondu unsafe buildings; the recent 1992 Erzincan earthquake. Narrated by Seán Barrett (actor), directed by Nick Read, produced by Bill Redway, made by October Films 28 November Space Shuttle Discovery, the Johnson Space Center in Texas, and the ACTS satellite (launched in September 1993 on STS-51) and the shuttle pallet satellite (SPAS) system; the 57th mission of the shuttle - STS-51; Commander Frank L.
Sources: en.wikipedia.org
== Risk factors == Glaucoma can affect anyone. Some people have a higher risk or susceptibility to develop glaucoma due to certain risk factors, including increasing age, high intraocular pressure, a family history of glaucoma, and use of steroid medications.
== Histopathology == Although the exact cause of this condition is not known, it is an inflammatory disorder characterized by collagen degeneration, combined with a granulomatous response. It always involves the dermis diffusely, and sometimes also involves the deeper fat layer. Commonly, dermal blood vessels are thickened (Microangiopathy). It can be precipitated by local trauma, though it often occurs without any injury. As a metabolically driven skin disorder, the pathology is characterized by poor intracellular glucose utilization leading to metabolically stressed fibroblasts. Despite an increased GLUT-1 response, fibroblasts in NL fail to produce normal collagen, weakening and breaking down the skin's structure. Vascular impairments reduce oxygen and nutrient circulation, creating hypoxia and tissue breakdown.
However, unjustified self-medicated preventive administration of stable KI is not recommended in order to avoid disturbing the normal thyroid function. Such a treatment must be carefully dosed and requires an appropriate KI amount prescribed by a specialised physician.
Rattlesnakes are native to the Americas from southern Canada to central Argentina, with the majority of species inhabiting arid regions. The large majority of species live in the American Southwest and Mexico. Four species may be found east of the Mississippi River, and two in South America. In the United States, the state with the most types of rattlesnakes is Arizona, with 13. Rattlesnakes are found in almost every habitat type capable of supporting terrestrial ectothermic vertebrates, but individual species may have extremely specific habitat requirements, living where certain plant associations occur or within a narrow range of elevations. Most species live near open, rocky areas. Rocks offer them cover from predators, plentiful prey (e.g. rodents, lizards, insects, etc. that live amidst the rocks), and open basking areas. However, rattlesnakes can also be found in a wide variety of other habitats, including prairies, marshes, deserts, and forests. Rattlesnakes prefer a temperature range between 80 and 90 °F (27 and 32 °C), but can survive temperatures below freezing, recovering from brief exposure to temperatures as low as 4 °F (−16 °C), and surviving for several days in temperatures as low as 37 °F (3 °C). The most probable ancestral area of rattlesnakes is the Sierra Madre Occidental region in Mexico. The most probable vegetation or habitat of the ancestral area appears to be pine-oak forests.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.